On July 28, Aimed Alliance sent a letter to the Centers for Consumer Information and Insurance Oversight (CCIIO) and the…
Prior to the Maryland Prescription Drug Affordability Board’s July meeting to conduct cost affordability reviews for Farxiga and Jardiance, Aimed…
On July 4, 2025, President Trump signed the One Big Beautiful Bill Act into law, notably without a controversial provision…
Washington, D.C. — June 30, 2025 — The not-for-profit Aimed Alliance, released a comprehensive new report analyzing how state policies…
Aimed Alliance and HR.com have launched a new webpage highlighting our 2024 survey findings; infographic, and webinar for employers and…
The Oregon Prescription Drug Affordability Board is currently reviewing the affordability of 27 selected medications and has requested feedback from…
On April 22, 2025, Aimed Alliance released a new resource titled “Tariffs 101: How Tariffs Could Impact Patients.” Since the start…
On January 14, 2024, the Federal Trade Commission (FTC) released its second report investigating the pharmacy benefit manager (PBM) industry.…
Currently, Medicare coverage for anti-obesity medications is limited to indications for diabetes and cardiovascular disease. Policymakers, however, have proposed expanding…
On October 10, 2024, the National AI Advisory Committee released its draft transition plan for the incoming administration. The…